BioStock Studio: Scandion Oncology outlines vision to fight cancer drug resistance
Scandion Oncology is a Danish biotech company developing treatments aimed at counteracting cancer drug resistance. Currently in phase II with its top candidate SCO-101, the company is raising capital through a rights issue and has partnering in its sights. Scandion Oncology’s CEO Bo Rode Hansen joined BioStock via video link to tell us more about the company and what makes SCO-101 first-in-class drug candidate.
Watch the full company presentation and Q&A with Scandion Oncology's CEO Bo Rode Hansen at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se